<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507845</url>
  </required_header>
  <id_info>
    <org_study_id>RAMIP_L_01961</org_study_id>
    <nct_id>NCT00507845</nct_id>
  </id_info>
  <brief_title>Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina</brief_title>
  <acronym>RAFEHELP</acronym>
  <official_title>Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary:

        -  To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients

      Secondary:

        -  To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean changes in Systolic Blood Pressure (SBP)</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean changes in Diastolic Blood Pressure (DBP)</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders with regard to DBP and SBP</measure>
    <time_frame>comparison to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>After treatment and at each follow-up visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">271</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril-Felodipine</intervention_name>
    <description>Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).</description>
    <other_name>Triacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient

          -  Patients who couldn´t control their hypertension after 6 weeks of treatment with
             monotherapy (calcium blockers, beta blockers, diuretics, ACE inhibitors, AT2
             blockers)(uncontrolled hypertension).

        Exclusion Criteria:

          -  Already on fixed-dose combination treatment for hypertension

          -  Contraindication to angiotensin converting enzyme (ACE) inhibitors or CCB therapy

          -  Known hypersensitivity to felodipine (or other dihydropyridines), ramipril, other ACE
             or any of the excipients of ramipril felodipine.

          -  History of angioedema

          -  Unstable haemodynamic conditions: cardiovascular shock, untreated heart failure, acute
             myocardial infarction, unstable angina pectoris, stroke.

          -  Patients with AV block II or III

          -  Severely impaired hepatic function.

          -  Pre-existing bilateral renal artery stenosis or stenosis of the artery to a solitary
             kidney

          -  Pregnant and lactating mothers

          -  Patients on dialysis or haemofiltration.

          -  Patients with creatinine clearance &lt; 20ml/min

          -  Use of potassium sparing diuretics

          -  Severe hypertension (SBP ≥ 180 mmhg or DBP ≥ 110 mmhg)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristian von Schulz Hausmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2007</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Felodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

